Are You Prepared To Move A Bioconjugate Candidate From Clinic To Market?

Antibody drug conjugates (ADCs) have become a groundbreaking tool in the industry’s fight against cancer, offering new opportunities for innovation and progress in patient care. These highly targeted biopharmaceutical drugs are one of the fastest growing anticancer drugs, with nine of the ten ADCs currently on the market approved just in the last decade and more than 80 ADCs in today’s pipeline.¹ Beside ADCs, bioconjugates with non-cytotoxic modifications are emerging and are on the verge of market authorization. Nevertheless, despite the potential of ADCs and other bioconjugates, they present a wide range of challenges for drug manufacturers trying to navigate their way to commercial success.